Efficacy of Dexmedetomidine for MECT

Comparative study of Ketofol with and without Dexmedetomidine for attenuation of post Modified electro convulsive therapy hyperdynamic response, agitation and depression. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/106682

Enrollment

Registered

2026-03-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F332- Major depressive disorder, recurrent severe without psychotic features

Interventions

Intervention1: DEXMEDETOMIDINE: ROLE OF DEXMEDETOMIDINE and KETOFOL COMBINATION IN MECT Control Intervention1: Ketamine propofol: KETOFOL IN MECT

Eligibility

Inclusion criteria

Inclusion criteria: All consented patients aged between 18-60 years belonging to ASA PS I - II planned for MECT under GA

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
To assess the hemodynamic changes during MECT i.e. Mean arterial pressure Pulse oximetry Heart rate Continuous ECG monitoringTimepoint: From T0 to T11 reading in which time is recorded every 5 minute intervals.	—

Secondary

Measure	Time frame
Agitation score - Patient satisfaction score - Hamilton depression rating scale.Timepoint: Patient satisfaction score - POST MECT, Agitation score - POST MECT, Hamilton depression rating scale - NEXT DAY	—

Countries

India

Contacts

Public ContactSaranshi singh

SPMC Bikaner

dranitapareek23@gmail.com9828101281

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026